# End-Stage Renal Disease

Manage kidney failure by identifying emergent dialysis indications, separating chronic uremic symptoms from reversible mimics, preparing renal replacement options before crisis, and initiating dialysis for refractory clinical complications rather than an isolated eGFR threshold.

**Clinical question:** How should physicians evaluate, prepare, and initiate kidney replacement therapy in patients with kidney failure?

Updated: 2026-08-24T17:47:59.025721+00:00

## What matters in practice
- Do not initiate maintenance dialysis solely for a low eGFR; start when kidney-failure symptoms, refractory metabolic abnormalities, uncontrolled volume or blood pressure, nutritional decline, or cognitive impairment cannot be managed medically. [11][12][20]
- Treat uremic encephalopathy, symptomatic pericardial effusion, refractory hyperkalemia, or refractory metabolic acidosis as indications for immediate dialysis. [18]
- Before attributing anorexia, fatigue, pruritus, cognitive complaints, or weight loss to uremia, evaluate and correct reversible causes and comorbid conditions that mimic the uremic syndrome. [10][21]
- Begin kidney failure education and planning by CKD stage 4 (eGFR 15-29 mL/min/1.73 m²), including transplantation, home or in-center hemodialysis, peritoneal dialysis, and conservative management. [12][14]
- Use creatinine-based eGFR cautiously in severe chronic illness, muscle wasting, or extreme body composition; cystatin C or measured GFR can resolve clinically consequential uncertainty. [10]

## Identify indications for urgent dialysis

Escalate for refractory complications, not for creatinine or eGFR alone.

Arrange immediate dialysis for uremic encephalopathy, symptomatic pericardial effusion, refractory hyperkalemia, or metabolic acidosis that persists despite medical management. Symptomatic uremia with nausea or vomiting also warrants dialysis when medical measures fail, irrespective of the measured GFR. [18]

For acute volume-related deterioration, determine whether pulmonary congestion, severe hypertension, or both remain uncontrolled despite medical therapy. Uncontrolled volume status or blood pressure is a kidney replacement therapy indication when medical management cannot achieve a safe clinical state. [11][12][21]

When possible, start dialysis gently in severe uremia because rapid solute removal can precipitate dialysis disequilibrium syndrome. The need for urgent treatment should not be deferred because residual kidney function appears numerically higher than expected for dialysis. [18][20]
- Assess mental status and examine for pericardial symptoms or effusion when encephalopathy, chest symptoms, or otherwise unexplained clinical deterioration occurs. [18]
- Obtain serum potassium and bicarbonate promptly when weakness, arrhythmia concern, nausea, dyspnea, or altered mentation raises concern for electrolyte or acid-base complications. [18]
- Assess weight trajectory, edema, blood pressure, and response to medical volume management before labeling fluid overload refractory. [11][21]

*Clinical triggers for dialysis escalation [11][18][21]*

| Clinical finding | Interpretation | Next action |
| --- | --- | --- |
| Uremic encephalopathy or symptomatic pericardial effusion | Uremic emergency [18] | Initiate immediate dialysis; avoid overly aggressive initial solute removal when feasible. [18] |
| Hyperkalemia or metabolic acidosis refractory to medical therapy | Life-threatening metabolic indication [18] | Initiate immediate dialysis. [18] |
| Volume overload or hypertension not controlled with medication | Refractory cardiorenal complication [11][21] | Initiate dialysis when medical therapy cannot establish safe volume status or blood pressure. [11][21] |
| Progressive nutritional decline despite dietary intervention | Kidney-failure complication requiring reassessment of conservative management [11][12] | Initiate or intensify preparation for dialysis after excluding reversible contributors. [11][12][21] |

## Confirm kidney failure and exclude reversible contributors

Distinguish advanced chronic disease from superimposed acute injury and symptom mimics.

Classify kidney failure at eGFR below 15 mL/min/1.73 m², but establish whether the deterioration is chronic, acute, or acute-on-chronic before committing to long-term kidney replacement planning. CKD requires a structural or functional kidney abnormality present for more than 3 months; acute kidney injury is defined by a rise in serum creatinine rather than by a fixed eGFR category. [9][15]

For a patient with suspected uremic symptoms, obtain urinalysis with microscopy, hemoglobin, calcium, phosphate, parathyroid hormone, albumin, potassium, and bicarbonate to assess potentially actionable contributors to symptoms and kidney-failure complications. [18]

Do not equate fatigue, anorexia, nausea, pruritus, sleepiness, impaired concentration, weight loss, or poor energy automatically with uremia. Correct reversible causes and evaluate competing comorbid disease before dialysis is chosen principally for nonspecific symptoms. This distinction is especially important in severe chronic illness and cardiorenal syndrome, in which muscle wasting can make creatinine-based eGFR misleadingly high. [10][21]
- Use eGFR plus urine protein or albumin quantification as the practical core of renal-function assessment. [17]
- When creatinine- and cystatin C-based estimates disagree, body composition is extreme, or a high-stakes kidney replacement or drug-dosing decision depends on true filtration, obtain cystatin C-based assessment or measured GFR with an exogenous marker such as iohexol. [10]
- For renal drug dosing, recognize that impaired filtration and tubular function prolong exposure to renally eliminated drugs and can cause bioaccumulation with repeated dosing. [1]

### Interpret reduced GFR in clinical context

An eGFR of 5-10 mL/min/1.73 m² is a common, but not obligatory, range at which dialysis begins when clinical indications develop. In an asymptomatic patient, no absolute GFR mandates dialysis; conversely, refractory uremic symptoms, hyperkalemia, or volume overload justify dialysis even if eGFR is above that range. [11][20]

*Testing that changes the interpretation of advanced CKD symptoms [10][17][18][21]*

| Problem | Test or assessment | Decision consequence |
| --- | --- | --- |
| Possible uremic syndrome | Urinalysis with microscopy; hemoglobin, calcium, phosphate, parathyroid hormone, albumin, potassium, and bicarbonate [18] | Identify metabolic, hematologic, or urinary abnormalities that require targeted correction or support kidney-failure assessment. [18] |
| eGFR likely biased by muscle wasting or unusual body composition | Cystatin C or measured GFR, including iohexol-based measurement when necessary [10] | Avoid misclassification and improve decisions about kidney replacement therapy or renally cleared drugs. [10] |
| Nonspecific fatigue, anorexia, pruritus, or cognitive symptoms | Evaluate reversible causes and comorbid conditions before attributing symptoms to uremia [21] | Avoid dialysis initiation for symptoms that may not improve with kidney replacement therapy. [21] |

## Initiate maintenance dialysis by clinical indication

Use symptom burden, refractory complications, nutritional trajectory, and patient goals.

Initiate maintenance dialysis when one or more complications attributable to kidney failure persist despite conservative treatment: uremic symptoms or signs, acid-base or electrolyte abnormalities, inability to control volume status or blood pressure, progressive nutritional deterioration despite dietary intervention, or cognitive impairment. [11][12]

Avoid a preemptive eGFR-based start in otherwise asymptomatic advanced CKD. In a randomized trial of 828 stage 5 patients assigned to an early eGFR target of 10-15 versus a late target of 5-7 mL/min/1.73 m², survival and adverse outcomes did not differ; patients assigned to later initiation often started earlier because of fluid overload or other complications. [14]

For patients without clear symptoms or refractory complications, continue close clinical surveillance and use shared decision-making rather than forcing dialysis at a fixed filtration threshold. NICE advises considering dialysis for the impact of uremic symptoms on daily living, biochemical abnormalities, uncontrollable fluid overload, or an eGFR of approximately 5-7 mL/min/1.73 m² in the absence of symptoms. [11]
- Document whether symptoms impair daily function and whether a reversible nonrenal cause has been addressed before offering dialysis principally for symptom relief. [11][21]
- Track nutritional status longitudinally; progressive deterioration refractory to dietary intervention is a dialysis indication rather than a reason to wait for a lower eGFR. [11][12]
- Reassess the treatment plan promptly after an unplanned hospitalization for fluid overload, hyperkalemia, acidosis, or uremic manifestations. [18][20]

*Maintenance dialysis timing framework [11][12][14][20]*

| Clinical state | Dialysis timing | Rationale |
| --- | --- | --- |
| Asymptomatic advanced CKD without refractory metabolic or volume complication | Defer dialysis while preparing a kidney replacement plan and monitoring closely. [20] | No absolute GFR requires dialysis in the absence of clinical indications. [20] |
| Persistent uremic manifestations, nutritional decline, cognitive impairment, or medically uncontrolled volume or blood pressure | Initiate maintenance dialysis. [11][12] | These are symptom- and complication-based indications for kidney replacement therapy. [11][12] |
| eGFR approximately 5-7 mL/min/1.73 m² without symptoms | Consider dialysis in the broader clinical context. [11] | This is a consideration threshold, not a replacement for clinical assessment. [11][20] |

## Prepare modality, access, and conservative care before crisis

Advance planning reduces the need for emergent dialysis starts.

At CKD stage 4, defined by eGFR 15-29 mL/min/1.73 m², provide structured counseling on kidney transplantation, peritoneal dialysis, home hemodialysis, in-center hemodialysis, and conservative management. Include family members and caregivers when appropriate because modality decisions affect home support, logistics, and goals of care. [12][14]

For a patient choosing hemodialysis, discuss vascular access and obtain vein mapping during stage 4; vascular access is generally placed at that stage when dialysis is anticipated. For peritoneal dialysis, plan access months before kidney replacement is expected to avoid complications associated with an emergent start. [14][18]

Refer transplant-eligible patients for transplant evaluation during progressive CKD rather than waiting until dialysis dependence. In patients who are clear progressors, discussion of renal replacement options should begin in late stage 3, tailored to the individual trajectory and candidacy. [14]
- Use the 4-variable Kidney Failure Risk Equation as an adjunct to eGFR and albuminuria when estimating the likelihood of kidney replacement therapy and structuring referral. [13][15]
- A 5-year kidney replacement therapy risk greater than 5% is a specialist-referral criterion in NICE guidance, with comorbidities and patient wishes incorporated into the decision. [15]
- If long-term conservative management is selected, continue active symptom assessment and revise the plan when refractory volume, metabolic, nutritional, or uremic complications emerge. [12][18]

### Medication safety during transition

Review all renally eliminated medications at each major decline in kidney function and before dialysis initiation. Reduced glomerular filtration and tubular function increase drug half-life and total exposure; mitigate accumulation by lowering the dose or reducing dosing frequency when supported by the individual drug regimen. [1]

*Planned kidney-failure transition actions [12][14][15][18]*

| Timing or trigger | Action | Purpose |
| --- | --- | --- |
| CKD stage 4, eGFR 15-29 mL/min/1.73 m² | Counsel regarding transplant, peritoneal dialysis, home or in-center hemodialysis, and conservative management. [12] | Enable informed modality selection before urgent treatment is required. [12] |
| Stage 4 with anticipated hemodialysis | Discuss access and obtain vein mapping; usually place vascular access at this stage. [14] | Reduce dependence on emergent dialysis access. [14] |
| Progressive CKD with transplant candidacy | Refer for transplant-program consideration. [14] | Allow assessment before dialysis dependence. [14] |
| 4-variable KFRE 5-year risk greater than 5% | Refer for specialist assessment while considering wishes and comorbidities. [15] | Risk-based referral supplements eGFR and albuminuria assessment. [15] |

## Monitor complications that drive dialysis decisions

Trend clinical status and correct reversible complications before escalating chronic therapy.

At each advanced CKD review, reassess volume status, blood pressure, uremic symptom burden, cognition, dietary intake, weight trajectory, potassium, and bicarbonate. Dialysis decisions should follow failure to safely manage these abnormalities medically, not a single laboratory or eGFR value. [11][12][20]

Monitor hemoglobin, calcium, phosphate, parathyroid hormone, and albumin alongside potassium and bicarbonate when evaluating uremia or progression toward kidney replacement therapy. These measures help identify anemia, mineral-metabolic abnormalities, impaired nutrition, electrolyte derangement, and acid-base disturbance that may require targeted management or accelerate the need for dialysis. [18]

For anemia-related iron assessment, NICE recommends testing every 3 months, or every 1-3 months in people receiving hemodialysis. If available with sample processing within 6 hours, a hypochromic red-cell percentage above 6% supports iron deficiency assessment; otherwise, reticulocyte hemoglobin content below 29 pg or an equivalent assay may be used. [15]
- Escalate the treatment plan when medical therapy no longer controls hyperkalemia, acidosis, hypertension, or volume overload. [11][18]
- Reassess symptom attribution after correcting anemia, metabolic disturbances, and other reversible contributors; persistent symptoms that remain attributable to kidney failure support dialysis initiation. [18][21]
- Repeat renal drug review when eGFR changes materially, during acute illness, and when starting medications with narrow therapeutic windows or critical renal elimination. [1][10]

*Longitudinal monitoring tied to management decisions [1][11][15][18]*

| Domain | Measure | Actionable interpretation |
| --- | --- | --- |
| Metabolic and acid-base status | Potassium and bicarbonate [18] | Refractory hyperkalemia or acidosis is an urgent dialysis indication. [18] |
| Volume and blood pressure | Weight trajectory, examination, and blood pressure [11][21] | Failure of medical management to control volume or blood pressure supports dialysis initiation. [11][21] |
| Nutrition and uremic burden | Dietary intake, weight loss, albumin, and cognitive or uremic symptom assessment [11][18] | Progressive deterioration despite intervention supports kidney replacement therapy. [11][12] |
| Iron status in CKD anemia | Every 3 months; every 1-3 months during hemodialysis; % hypochromic red cells, reticulocyte hemoglobin content, or equivalent [15] | Use % hypochromic red cells above 6% when timely processing is available, or reticulocyte hemoglobin content below 29 pg when it is not. [15] |
| Medication accumulation | Medication reconciliation and renal-function assessment [1] | Reduce dose or dosing frequency of inadequately cleared drugs as appropriate to limit bioaccumulation. [1] |

## References
1. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2016.02.082
2. Hemodialysis vascular access flow surveillance — journals.lww.com — https://journals.lww.com/jcma/_layouts/15/oaks.journals/downloadpdf.aspx?an=02118582-202511000-00004
3. Advancing Transplantation : Transplantation — journals.lww.com — https://journals.lww.com/transplantjournal/fulltext/2017/02001/advancing_transplantation__new_questions,_new.1.aspx
4. Long‐Term Outcome Analysis of Peritoneal Dialysis... : Hemodialysis International — journals.lww.com — https://journals.lww.com/01052346-202510000-00022
5. Chronic kidney disease–mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S008525382400810X
6. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0085253819301383
7. Chronic Kidney Disease-Mineral and Bone Disorder — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/chronic-kidney-disease-mineral-and-bone-disorder
8. Early Versus Late Initiation of Dialysis in CKD Stage 5 — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2468024924019508
9. Imaging Patients with Kidney Failure — pubs.rsna.org — https://pubs.rsna.org/doi/pdf/10.1148/rg.220116
10. Assessment of kidney function: clinical indications for measured GFR — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8323140
11. Early Versus Late Initiation of Dialysis in CKD Stage 5: Time for a Consensus — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11725814
12. Hemodialysis - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK563296
13. Risk-based versus GFR threshold criteria for nephrology ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9613424
14. Chronic kidney disease in the elderly: evaluation and management — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4291282
15. Chronic kidney disease: assessment and management — www.nice.org.uk — https://www.nice.org.uk/guidance/ng203/chapter/recommendations
16. When to initiate dialysis for end-stage kidney disease — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/30208820
17. Renal Function Tests - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK507821
18. Uremia - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK441859
19. Timing of Dialysis Initiation: What Has Changed Since ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0270929516301383
20. Timing of Dialysis Initiation - What Has Changed Since IDEAL? — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5407409
21. Chinese Clinical Practice Guideline for the Management of “CKD-PeriDialysis”-the Periods Prior to and in the Early-Stage of Initial Dialysis — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9782818
22. Assessment and management of heart failure in patients with chronic kidney disease - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10942934

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.